SPECIAL FEATURES

CCR Pediatric Oncology Series
Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:
clinicancerres.aacrjournals.org/pediatricseries

e91 Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient

e98 Retinoblastoma and Neuroblastoma Predisposition and Surveillance

e107 Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood

e115 Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma

e123 Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Highlights of This Issue 3227

CCR Translations

3229 The Microbiota: A New Variable Impacting Cancer Treatment Outcomes
Jessica L. Fessler and Thomas F. Gajewski
See related article, p. 3263

Reviews

3232 Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair
Aimee Bene Lin, Samuel C. McNeely, and Richard P. Beckmann

3241 The Promise of Targeting Macrophages in Cancer Therapy
J. Martin Brown, Lawrence Recht, and Samuel Strober

3251 Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Debu Tripathy, Aditya Bardia, and William R. Sellers

PERSPECTIVE

3263 Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?
Jessica R. Galloway-Petra, Robert B. Jenq, and Samuel A. Shelburne
See related commentary, p. 3229

CANCER THERAPY: CLINICAL

3269 First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
PERSONALIZED MEDICINE AND IMAGING

3325 Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

3334 Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways
Jia Wu, Yi Cui, Xiaoli Sun, Guohong Cao, Bailiang Li, Debra M. Ikeda, Allison W. Kurian, and Ruijiang Li

3343 Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy

3352 Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Luciano Castielo, Marriana Sabatino, Iasijang Ren, Masaki Terabe, Hanh Khuu, Lauren V. Wood, Jay A. Berzofsky, and David F. Slonosky

3365 Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

CANCER THERAPY: PRECLINICAL

3371 PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt McClain, Gregory D. Ayers, Mark C. Kelley, Melinda Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, and Ann Richmond
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras Gonzalez, Antonio Cavazos, Rongqiang Pan, Hong Mu, Sa A. Wang, Jin Zhou, Cheetah Al-Atarsh, Stefan O. Ciureka, Mike Retrig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, and Marina Konopleva

Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo
Denise L. Cecil, Meredith Slota, Megan M. O'Meara, Benjamin C. Curtis, Ekram Gad, Yushe Dang, Daniel Herendeen, Lauren Rastetter, and Mary L. Disis

Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer
Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali A. Mostafa, and David M. Goldenberg

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

BIOLOGY OF HUMAN TUMORS

Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer
Ke Chen, Halbing Xiao, Jin Zeng, Gan Yu, Hui Zhou, Chunhua Huang, Weimin Yao, Wei Xiao, Junhui Hu, Wei Guan, Lily Wu, Jiaoti Huang, Qihong Huang, Hua Xu, and Zhangqun Ye

LETTER TO THE EDITOR

FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter
Brenda F. Kurland, Hannah M. Linden, and David A. Mankoff

FDG PET and FES PET Predict PFS on Endocrine Therapy—Response
Brenda F. Kurland, Hannah M. Linden, and David A. Mankoff
ABOUT THE COVER

The cover shows a section of a PyMT breast tumor treated with the pan PI3K inhibitor BKM120 (30 mg/kg daily) and PD-1-blocking antibody (100 μg twice a week). H&E staining reveals an extensive infiltration of immune cells into the treated tumors, which was associated with reduction in tumor growth and was not observed in control tumors. For details, see the article by Sai and colleagues on page 3371 of this issue.